Sunday, November 14, 2010

GlaxoSmithKline Attorney Hit with Obstruction Charge

Paying fines for alleged violations of the law are often seen as one of the costs of doing business. So in an effort to deter corporate wrongdoing, the government is stepping up prosecutions of individuals, namely executives, high-level employees and other decision-makers.
Back in March, The Wall Street Journal reported that the Food and Drug Administration planned to increase prosecutions of industry executives and corporate counsel.
Federal prosecutors have accused a former GlaxoSmithKline attorney of lying to obstruct a U.S. investigation into whether the pharmaceutical company illegally marketed an antidepressant as a weight-loss drug.
Here’s the complete coverage.

No comments:

Post a Comment

:: Up ::